Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

Rayaldee is the first and only extended-release prohormone of the active form of vitamin D3 for the treatment of SHPT1

Unique mechanism

  • Rayaldee is the only FDA-approved SHPT treatment that has been demonstrated to reduce iPTH and increase 25D1